• Investor Centre

    Oventus Medical (OVN) is an ASX listed company using Airway Technology to provide innovative breathing solutions to sufferers of snoring and obstructive sleep apnoea.

    Market Cap:  
    Price Delay ~20min

Board and Management

Board of Directors

The Company’s Board has a broad background of executive and non-executive board experience in the health and medical device industries and early stage companies, combined with publicly listed company, capital market, financial and commercial expertise. The board comprises:  

  • Ms Sue MacLeman

    Chair and Non-Executive Director

    Sue MacLeman has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development. Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the pharmaceutical sector. Sue is also appointed to several academic and government advisory committees including CSIRO Health and Biosecurity Advisory Committee, Prime Ministers Digital Expert Advisory Committee, DMTC Medical Countermeasures and various COVID19 taskforces.

    Sue commenced the role as Chair of Oventus Medical Ltd (ASX:OVN) in November 2020 along with Chair of Oventus’ Remuneration Committee. She is also Chair of MTPConnect (Medical Technology and Pharmaceuticals Industry Innovation Growth Centre Ltd MTPII-GC Ltd), Chair of Anatara Lifesciences Ltd (ASX:ANR), Chair of Tali Digital Ltd (ASX:TD1), Non-Executive Director of Palla Pharma Ltd (ASX:PAL) and Non-Executive Director of veski. Her broad commercial experience is underpinned by her qualifications including a Bachelor of Pharmacy (University of Queensland), Masters of Marketing at Melbourne University (Melbourne Business School) and a Masters of Law degree (Deakin University). Sue is also Fellow and Chair Health Forum ATSE, Fellow ACPP and Fellow/Graduate of AICD.

  • Dr Chris Hart

    Dr Chris Hart

    Founder, Managing Director and Chief Executive Officer

    Chris is the founder of the Company and inventor of the O2Vent design concept. Chris is overseeing the launch of the O2Vent to patients and through clinicians and heads the management team as they roll out the Oventus Sleep Treatment Platform across Australia, the United States and Canada. Chris is also heavily involved with training and presenting to the dental and sleep sector. Chris graduated from the University of Queensland in 1998 with a Bachelor of Dental Science with Honours and a Bachelor of Science in Biochemistry. He has studied at Cambridge University where he graduated with a Master of Philosophy in Biomedical Science in 1999. Prior to establishing Oventus, Chris owned and managed a multi-site national dental practice, training institute and management consultancy which he sold to private equity investors. Chris also acts as an adviser to various bodies within the dental industry on the commercial aspects of health care delivery.  

  • Dr Mel Bridges

    Dr Mel Bridges

    Non-Executive Director

    Mel has over 35 years’ experience founding and building international lifescience, diagnostic and medical device companies and commercialising a wide range of Australian technology. He is responsible for numerous commercial and M&A transactions and liquidity events, including listings on the ASX. Mel has received national and state business awards including the 2005 AusBiotech Chairman’s Industry Medal and 2004 Queensland Entrepreneur of the Year. Mel has founded and developed medical device and diagnostic companies, including Pacific Diagnostics (acquired by Baxter), PanBio Ltd (acquired by Inverness Medical), and ImpediMed Ltd (ASX: IPD). Mel retired from the role of Chair for Oventus in November 2020. He moved to a Non-Executive Director role and now chairs the Oventus Audit & Risk Committee.

  • Paul Molloy

    Non-Executive Director

    Based in Southern California, Paul Molloy has considerable global and US medical device industry expertise, with twenty-five years’ experience leading a range of public, private and venture capital funded healthcare companies. He is currently President and CEO of ClearFlow Inc., a US-based medical device company. Before joining ClearFlow, Paul was CEO at VasoNova Inc.- a Silicon Valley-based, venture funded vascular navigation company which was acquired by Teleflex Inc. (NYSE, TFX), in January 2011. Following the acquisition, he was appointed President of Teleflex’ largest division – ARROW Vascular – having full P&L responsibilities for direct sales, US and overseas manufacturing plants, R&D and strategic planning. Mr Molloy has also exited a number of leading US medical devices firms, including publicly traded cerebral oxygenation monitoring firm, CAS Medical Inc., and Revolutionary Medical Devices. He also serves on the Board at Augustine Medical a privately held market leader in medical arena temperature management and Inscope Inc., a venture capital-funded critical care firm. Paul started his career as a CRNA (Certified Registered Nurse Anesthetist). He holds an MBA (Chicago Booth School of Business) with a focus on finance and economics.

  • Jake Nunn

    Non-Executive Director

    Based in Menlo Park, CA, Jake Nunn has more than 25 years’ experience in the life science industry as an investor, independent director, research analyst and investment banker. Jake is currently a venture advisor at New Enterprise Associates (NEA), where he was a partner from 2006 to 2018. Jake is a Director of Addex Therapeutics (SIX,Nasdaq: ADXN), Qool Therapeutics, Inc., Regulus Therapeutics (Nasdaq: RGLS) and Trevena, Inc. (Nasdaq: TRVN). He was a previous Director of several companies in the pharmaceutical sector including Dermira Inc. (acquired by Eli Lilly) and Hyperion Therapeutics (acquired by Horizon Pharma plc), and a board observer at Vertiflex, Inc. (acquired by Boston Scientific).  Prior to NEA, Jake was a Partner specializing in life sciences investing at MPM Capital. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex. Brown & Sons.  Jake received an MBA from the Stanford Graduate School of Business and an AB in Economics from Dartmouth College. Jake holds the Chartered Financial Analyst designation, is a member of the CFA Society of San Francisco, and recently completed the Stanford GSB Directors’ Consortium executive education program.

  • Stephen Denaro

    Company Secretary

    Steve has extensive experience in mergers and acquisitions, business valuations, accountancy and income tax compliance services, as well as board corporate governance. Steve provides company secretary services for a number of biotech and software companies. Steve is also a member of the Institute of Chartered Accountants in Australia, and the Australian Institute of Company Directors.

Senior Management